This decision concerned a patent infringement action brought under s 6(1) of the Patented Medicines (Notice of Compliance) Regulations. The Plaintiffs’ patents at issue, Canadian Patent Nos. 2,591,083 (the “083 Patent”) and 2,726,267 (the “267 Patent”), relate to the innovative drug nintedanib, which is used to treat idiopathic pulmonary fibrosis (“IPF”), and marketed under the brand name OFEV®.